Nice Technical article about uLMS...and adjuvant therapy

I received adjuvant therapy (the GEM/TAX chemo) to kill the cancer cells that had not settled and started growing.

Here's a study that was done about this type of therapy. Cancer treatment is constantly changing as new therapies are available. This is an example. I'm also very pleased that my education for Health Information Administration gives me the skill to read complex articles like this one. Even bad news is news. We've tried this, now trying something else.


Expert Rev Anticancer Ther. 2015 Nov 11. [Epub ahead of print]

The role of adjuvant therapy in uterine leiomyosarcoma.

Ducie JA1, Leitao MM1, Jr MD1.

Abstract

Uterine leiomyosarcoma (uLMS) is a rare mesenchymal tumor of the gynecologic tract. Although diagnosed in only 1-3% of patients with uterine cancer, uLMS accounts for the majority of uterine cancer-related deaths. The standard of care for patients with uLMS includes total hysterectomy and bilateral salpingo-oophorectomy (BSO). There are no standard recommendations regarding adjuvant or palliative therapy. Many cytotoxic and targeted agents have been studied in clinical trials in an effort to identify an effective therapy that may alter the natural history of this disease. Unfortunately, as of now, there are no adjuvant therapy regimens that improve overall survival in this patient population. There is, therefore, an unmet need to identify a novel therapy that will improve the survival of women diagnosed with this aggressive disease. Here we summarize the existing literature on adjuvant therapy in uLMS, specifically highlighting advances made in the last 5 years.


KEYWORDS:

docetaxel; doxorubicin; gemcitabine; ifosfamide; mTOR inhibitor; pazopanib; trabectedin; uterine leiomyosarcoma